Citations

Mayo Clinic

Showing 10 of 108523 citations.

Remodeling of Displaced Condylar Fractures with Functional Treatment: High-Quality Radiographic Documentation in Three-Patient Series
Yıldırım, Yavuz , Keller, Eugene E., Yildirim, Yavuz

Craniomaxillofacial Trauma & Reconstruction | April 30, 2015 | Volume: 8 | Issue: 4 | Pages: 334-340

10.1055/s-0035-1550064 | PMID 26576239 Get It

Treatment of condylar fractures is variable and controversial. Treatment options for management of condylar fractures include surgical and nonsurgical methods, and if a nonsurgical method is as effective as a surgical method, the former is preferred. Although plain film radiographs and functional outcomes attained through nonsurgical treatment are well established in literature, evidence of the remodeling process through detailed, high-quality imaging is lacking. The purpose of this case series is to describe and illustrate two adults and one pediatric patient with significantly displaced condylar fractures treated nonsurgically with excellent clinical results. It is unique for such patients to have pre- and posttreatment computed tomography scans with high-quality three-dimensional reconstruction as in the case of two adults and to have 3.5-year posttrauma radiographs and 14.5-year follow-up as in the case of the pediatric patient. As such, this report is useful in visually presenting three examples of repositioning and reformation of the temporomandibular joint structures in displaced condylar fractures in a postmenarche 14-year-old female patient, a 21-year-old male patient, and an 18-month-old male patient.
The Gap in Big Data: Getting to Wellbeing, Strengths, and a Whole-person Perspective
Monsen, Karen A. , Schlesner, Sara, Vanderboom, Catherine E., Holland, Diane E. , Peters, Judith Carolien

Global Advances in Health and Medicine | April 30, 2015 | Volume: 4 | Issue: 3 | Pages: 31-39

10.7453/gahmj.2015.040 | PMID 25984416 Get It

Background: Electronic health records (EHRs) provide a clinical view of patient health. EHR data are becoming available in large data sets and enabling research that will transform the landscape of healthcare research. Methods are needed to incorporate wellbeing dimensions and strengths in large data sets. The purpose of this study was to examine the potential alignment of the Wellbeing Model with a clinical interface terminology standard, the Omaha System, for documenting wellbeing assessments. Objective: To map the Omaha System and Wellbeing Model for use in a clinical EHR wellbeing assessment and to evaluate the feasibility of describing strengths and needs of seniors generated through this assessment. Methods: The Wellbeing Model and Omaha System were mapped using concept mapping techniques. Based on this mapping, a wellbeing assessment was developed and implemented within a clinical EHR. Strengths indicators and signs/symptoms data for 5 seniors living in a residential community were abstracted from wellbeing assessments and analyzed using standard descriptive statistics and pattern visualization techniques. Results: Initial mapping agreement was 93.5%, with differences resolved by consensus. Wellbeing data analysis showed seniors had an average of 34.8 (range=22–49) strengths indicators for 22.8 concepts. They had an average of 6.4 (range=4–8) signs/symptoms for an average of 3.2 (range=2–5) concepts. The ratio of strengths indicators to signs/symptoms was 6:1 (range 2.8–9.6). Problem concepts with more signs/symptoms had fewer strengths. Conclusion: Together, the Wellbeing Model and the Omaha System have potential to enable a whole-person perspective and enhance the potential for a wellbeing perspective in big data research in healthcare.
Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion
Camilleri, Michael , Carlson, Paula, Busciglio, Irene, Acosta, Andrés

American Journal of Physiology-Gastrointestinal and Liver Physiology | April 30, 2015 | Volume: 309 | Issue: 1 | Pages: G10-G20

10.1152/ajpgi.00080.2015 | PMID 25930081 Get It

The mucosal gene expression in rectosigmoid mucosa (RSM) in irritable bowel syndrome with diarrhea (IBS-D) is unknown. Our objectives were, first, to study mRNA expression [by RT2 PCR of 19 genes pertaining to tight junctions, immune activation, intestinal ion transport and bile acid (BA) homeostasis] in RSM in IBS-D patients ( n = 47) and healthy controls ( n = 17) and study expression of a selected protein (PDZD3) in 10 IBS-D patients and 4 healthy controls; second, to assess RSM mRNA expression according to genotype and fecal BA excretion (high ≥2,337 μmol/48 h); and third, to determine whether genotype or mucosal mRNA expression is associated with colonic transit or BA parameters. Fold changes were corrected for false detection rate for 19 genes studied ( P < 0.00263). In RSM in IBS-D patients compared with controls, mRNA expression of GUC2AB, PDZD3, and PR2Y4 was increased, whereas CLDN1 and FN1 were decreased. One immune-related gene was upregulated (C4BP4) and one downregulated (CCL20). There was increased expression of a selected ion transport protein (PDZD3) on immunohistochemistry and Western blot in IBS-D compared with controls ( P = 0.02). There were no significant differences in mucosal mRNA in 20 IBS-D patients with high compared with 27 IBS-D patients with normal BA excretion. GPBAR1 ( P < 0.05) was associated with colonic transit. We concluded that mucosal ion transport mRNA (for several genes and PDZD3 protein) is upregulated and barrier protein mRNA downregulated in IBS-D compared with healthy controls, independent of genotype. There are no differences in gene expression in IBS-D with high compared with normal fecal BA excretion.
iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling
Li, Xue , Maretzky, Thorsten , Weskamp, Gisela, Monette, Sébastien , Qing, Xiaoping, Issuree, Priya D. , McIlwain, David R. , Mak, Tak W. , Blobel, Carl , Crawford, Howard C, Crawford, Howard C. , Salmon, Jane E.

Proceedings of the National Academy of Sciences | April 30, 2015 | Volume: 112 | Issue: 19 | Pages: 6080-6085

10.1073/pnas.1505649112 | PMID 25918388 Get It

Significance The skin and intestinal barrier are controlled by signaling scissors, termed ADAM17 (a disintegrin and metalloprotease 17), that reside in the membrane on the surface of cells. The main purpose of these signaling scissors is to liberate growth factors from their membrane anchor, allowing them to activate their receptors, including the epidermal growth factor receptor (EGFR). The ADAM17/EGFR signaling axis is tightly regulated, yet little is known about the underlying mechanism. Here we use genetic, cell biological, and biochemical approaches to identify two membrane proteins termed iRhoms 1 and 2 (inactive Rhomboid-like proteins) as crucial upstream regulators of ADAM17-dependent EGFR signaling. This uncovers the iRhoms as attractive novel targets to treat ADAM17/EGFR-dependent diseases such as cancer.
Update in Perioperative Medicine: Evidence Published in 2014
Mauck, Karen F. , Sundsted, Karna K.

Annals of Internal Medicine | April 30, 2015 | Volume: 162 | Issue: 9 | Pages: W111-W116

10.7326/m15-0206 | PMID 25927736 Get It

Dentists On Stamps
Shampo, Marc A., Gibilisco, Joseph A.

Journal of Clinical Pediatric Dentistry | April 30, 2015 | Volume: 31 | Issue: 4 | Pages: 222-224

10.17796/jcpd.31.4.507j1h27p3x652u3 | PMID 19161054 Get It

5‐year follow‐up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial
Wagner‐Johnston, Nina D. , Sloan, Jeff A. , Liu, Heshan , Kearns, Ann E. , Hines, Stephanie L., Puttabasavaiah, Suneetha, Dakhil, Shaker R. , Lafky, Jacqueline M., Perez, Edith A. , Loprinzi, Charles L.

Cancer | April 30, 2015 | Volume: 121 | Issue: 15 | Pages: 2537-2543

10.1002/cncr.29327 | PMID 25930719 Get It

BACKGROUNDPostmenopausal women with breast cancer receiving aromatase inhibitors are at an increased risk of bone loss. The current study was undertaken to determine whether upfront versus delayed treatment with zoledronic acid (ZA) impacted bone loss. This report described the 5‐year follow‐up results.METHODSA total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment were randomized to either upfront (274 patients) or delayed (277 patients) ZA at a dose of 4 mg intravenously every 6 months. In the patients on the delayed treatment arm, ZA was initiated for a postbaseline bone mineral density T‐score of <‐2.0 or fracture.RESULTSThe incidence of a 5% decrease in the total lumbar spine bone mineral density at 5 years was 10.2% in the upfront treatment arm versus 41.2% in the delayed treatment arm (P<.0001). A total of 41 patients in the delayed treatment arm were eventually started on ZA. With the exception of increased NCI Common Toxicity Criteria (CTC) grade 1/2 elevated creatinine and fever in the patients treated on the upfront arm and cerebrovascular ischemia among those in the delayed treatment arm, there were no significant differences observed between arms with respect to the most common adverse events of arthralgia and back pain. Osteoporosis occurred less frequently in the upfront treatment arm (2 vs 8 cumulative cases), although this difference was not found to be statistically significant. Bone fractures occurred in 24 patients in the upfront treatment arm versus 25 patients in the delayed treatment arm.CONCLUSIONSImmediate treatment with ZA prevented bone loss compared with delayed treatment in postmenopausal women receiving letrozole and these differences were maintained at 5 years. The incidence of osteoporosis or fractures was not found to be significantly different between treatment arms. Cancer 2015;121:2537–2543. © 2015 American Cancer Society.
Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes
Leis, José F., Chaffee, Kari G. , Call, Timothy G. , Hanson, Curtis A. , Chanan‐Khan, Asher , Bowen, Deborah A., Conte, Michael, Schwager, Susan M., Dyke, Daniel L. Van , Jelinek, Diane F., Rabe, Kari G. , Chanan-Khan, Asher A., Bowen, Deborah, Schwager, Susan, Van Dyke, Daniel L, Parikh, Sameer A. , Ding, Wei , Slager, Susan L. , Kay, Neil E. , Shanafelt, Tait D.

Cancer | April 30, 2015 | Volume: 121 | Issue: 17 | Pages: 2883-2891

10.1002/cncr.29438 | PMID 25931291 Get It

BACKGROUND Although hypogammaglobulinemia is a well recognized complication in patients with chronic lymphocytic leukemia (CLL), its prevalence at the time of CLL diagnosis, and association with novel prognostic markers and clinical outcome is not well understood. METHODS All patients at the Mayo Clinic between January 1999 and July 2013 who had newly diagnosed CLL and had a baseline assessment of serum immunoglobulin G (IgG) were included. The relation between hypogammaglobulinemia at diagnosis and the novel prognostic parameters time to first treatment (TFT) and overall survival (OS) were evaluated. RESULTS Of 1485 patients who met the eligibility criteria, 382 (26%) had hypogammaglobulinemia (median IgG, 624 mg/dL), whereas the remaining 1103 patients (74%) had normal serum IgG levels (median IgG, 1040 mg/dL). Patients who had hypogammaglobulinemia at diagnosis were more likely to have advanced Rai stage (III‐IV; P = .001) and higher expression of CD49d ( P < .001) compared with patients who had normal IgG levels. Although the median TFT for patients who had hypogammaglobulinemia was shorter compared with that for patients who had normal IgG levels (3.8 years vs 7.4 years; P < .001), on multivariable analysis, there was no difference in OS between these 2 groups (12.8 years vs 11.3 years, respectively; P = .73). Of 1103 patients who had CLL with normal IgG levels at diagnosis and who did not receive CLL therapy, the risk of acquired hypogammaglobulinemia was 11% at 5 years and 23% at 10 years. CONCLUSIONS Hypogammaglobulinemia is present in 25% of patients with newly diagnosed CLL. Approximately 25% of patients who have CLL with normal IgG levels at diagnosis will subsequently develop hypogammaglobulinemia on long‐term follow‐up. The presence of hypogammaglobulinemia does not appear to impact overall survival. Cancer 2015;121:2883–2891. © 2015 American Cancer Society .
Secondary cutaneous involvement by systemic anaplastic lymphoma kinase‐negative anaplastic large‐cell lymphoma with 6p25.3 rearrangement
Feldman, Andrew L. , Grogg, Karen L., Knudson, Ryan A., Inwards, David J. , Feldman, Andrew L

Histopathology | April 30, 2015 | Volume: 67 | Issue: 6 | Pages: 932-935

10.1111/his.12729 | PMID 25930107 Get It

Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up
Bajric, Jasmina, Bakri, Sophie J.

Seminars in Ophthalmology | April 30, 2015 | Volume: 31 | Issue: 6 | Pages: 542-547

10.3109/08820538.2015.1009555 | PMID 25927243 Get It